Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

Project Information

VSV-EBOVAC

Grant agreement ID: 115842

DOI

10.3030/115842

Project closed

EC signature date 19 March 2015

Start date 1 March 2015

End date 28 February 2019

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 4 786 010,00

EU contribution

€ 3 887 260,00

Coordinated by

SCLAVO VACCINES ASSOCIATION
Italy

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (5)

Distribution of intermediate samples (day 28) to partners involved in immunogenicity studies

Migration

Predictive correlates of protective immunity and safety determined.

Migration

Establishment of the External Advisory Board

Migration

Distribution of late samples (> day 28) to partners involved in immunogenicity studies

Migration

Distribution of early samples (day 0-14) to partners involved in immunogenicity studies

Migration

Websites, patent fillings, videos etc. (1)

Web site development and maintenance

Migration

Publications

Peer reviewed articles (6)

Ebola vaccine R&D: Filling the knowledge gaps

Author(s): Donata Medaglini, Ali M. Harandi, Tom H. M. Ottenhoff, Claire-Anne Siegrist, VSV-EBOVAC Consortium
Published in: Science Translational Medicine, Issue 7/317, 2015, Page(s) 317ps24-317ps24, ISSN 1946-6234
Publisher: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.aad3106

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Author(s): Donata Medaglini, Claire-Anne Siegrist
Published in: Current Opinion in Virology, Issue 23, 2017, Page(s) 88-94, ISSN 1879-6257
Publisher: Elsevier BV
DOI: 10.1016/j.coviro.2017.03.008

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Author(s): Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER,
Published in: The Lancet Infectious Diseases, Issue 18/7, 2018, Page(s) 738-748, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/S1473-3099(18)30165-8

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa

Author(s): Angela Huttner, Christophe Combescure, Stéphane Grillet, Mariëlle C. Haks, Edwin Quinten, Christine Modoux, Selidji Todagbe Agnandji, Jessica Brosnahan, Julie-Anne Dayer, Ali M. Harandi, Laurent Kaiser, Donata Medaglini, Tom Monath, Pascale Roux-Lombard, Peter G. Kremsner, Tom H. M. Ottenhoff, Claire-Anne Siegrist
Published in: Science Translational Medicine, Issue 9/385, 2017, Page(s) eaaj1701, ISSN 1946-6234
Publisher: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.aaj1701

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Author(s): Angela Huttner, Claire-Anne Siegrist
Published in: Expert Review of Vaccines, Issue 17/12, 2018, Page(s) 1105-1110, ISSN 1476-0584
Publisher: Future Drugs Ltd.
DOI: 10.1080/14760584.2018.1546582

Correlates of vaccine-induced protective immunity against Ebola virus disease

Author(s): Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Published in: Seminars in Immunology, Issue 39, 2018, Page(s) 65-72, ISSN 1044-5323
Publisher: Academic Press
DOI: 10.1016/j.smim.2018.07.003